News

Azithromycin, Ibuprofen, Hydroxychloroquine Prices Rise: NPPA Approves 1.74% Hike from April 1

The price adjustment impacts crucial medications used for infections, heart conditions, diabetes, and pain relief. The NPPA, which regulates medicines under the National List of Essential Medicines (NLEM), determines price changes based on inflation and production costs. The 1.74% increase this year is calculated from the WPI rise for 2024 over 2023.

• By Pooja Chaturvedi Sah
• New Delhi
• Apr 01, 2025

News

The National Pharmaceutical Pricing Authority (NPPA) has increased the prices of over 900 essential medicines by up to 1.74%, effective today. The price adjustment impacts crucial medications used for infections, heart conditions, diabetes, and pain relief. The revision follows the annual Wholesale Price Index (WPI)-linked update, ensuring pharmaceutical pricing aligns with market trends.

Government Justifies Annual Price Adjustment

The NPPA, which regulates medicines under the National List of Essential Medicines (NLEM), determines price changes based on inflation and production costs. The 1.74% increase this year is calculated from the WPI rise for 2024 over 2023.

"Based on the WPI data provided by the Office of the Economic Adviser, Department for Promotion of Industry and Internal Trade, manufacturers are permitted to increase maximum retail prices of scheduled formulations without requiring prior government approval," the NPPA stated in an official release.

Minister of State for Chemicals and Fertilizers, Anupriya Patel, reiterated in Lok Sabha that the adjustment is aimed at balancing affordability with industry sustainability.

Common Medicines Affected by the Price Increase

Many widely used drugs will see a price hike starting today. The revised ceiling prices are as follows:

• Azithromycin (antibiotic): ₹11.87 for 250mg and ₹23.98 for 500mg per tablet.
• Amoxicillin + Clavulanic Acid (antibiotic dry syrup): ₹2.09 per ml.
• Acyclovir (antiviral): ₹7.74 for 200mg and ₹13.90 for 400mg per tablet.
• Hydroxychloroquine (anti-malarial): ₹6.47 for 200mg and ₹14.04 for 400mg per tablet.
• Diclofenac (painkiller): ₹2.09 per tablet.
• Ibuprofen (painkiller): ₹0.72 for 200mg and ₹1.22 for 400mg per tablet.
• Dapagliflozin + Metformin Hydrochloride + Glimepiride (diabetes medication): ₹12.74 per tablet.

Manufacturers can now implement these revised prices, ensuring compliance with NPPA regulations.

Why the Price Hike?

The NPPA annually revises the cost of essential medicines based on WPI changes, ensuring affordability while accounting for inflation and production costs. This mechanism helps regulate drug prices without compromising pharmaceutical industry viability.

The NLEM, comprising 384 medicines, undergoes periodic revisions to include new treatments and remove outdated formulations. The 2022 update added 34 new drugs while removing 26.

History and Background of India's Essential Medicines Pricing

India's first National List of Essential Medicines (NLEM) was introduced in 1996, listing 279 medicines crucial for public health. It was subsequently revised in 2003, 2011, 2015, and most recently in 2022 to reflect changing disease patterns and medical advancements.

The list plays a critical role in drug price control, ensuring that medicines remain accessible while balancing industry sustainability. The NPPA, established in 1997, enforces price controls and monitors pharmaceutical market dynamics.

How Drug Prices Are Controlled

For medicines under NLEM, NPPA determines ceiling prices by averaging market prices of all brands with a market share of at least 1%. This strategy prevents exorbitant pricing while ensuring fair compensation for manufacturers.

For non-NLEM medicines, price increases are capped at 10% annually, preventing uncontrolled price surges.

India’s Essential Medicines Framework Aligned with Global Standards

India’s NLEM is modeled after the World Health Organization’s Essential Medicines List (EML), prioritizing drugs vital to public health. The first WHO EML was introduced in 1977, and India adopted a similar approach to guide healthcare policy and public sector procurement.

The NLEM categorizes medicines based on their necessity at primary, secondary, and tertiary healthcare levels, ensuring equitable access.

Broader Impact on Patients and Healthcare

While the NPPA ensures that price adjustments are regulated, the increase may still pose challenges for patients who rely on these essential medicines. Experts have raised concerns about the affordability of critical drugs, particularly for low-income groups. Healthcare providers may also need to adjust prescription strategies to accommodate price-sensitive patients.

Additionally, the price hike may have a cascading effect on hospital expenses and insurance coverage, as essential medicines form the backbone of treatment protocols in both public and private healthcare sectors.

With today's price adjustments, healthcare providers and consumers will need to account for increased costs. While the government assures that the hikes are necessary for a sustainable pharmaceutical market, the impact on affordability remains a concern for many patients.